An Open Label, Two Stage, Phase II Study to Evaluate the Efficacy and Tolerability of ZD6474 in Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Carcinoma
Phase of Trial: Phase II
Latest Information Update: 18 Jul 2017
At a glance
- Drugs Vandetanib (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 19 Jun 2017 Status changed from active, no longer recruiting to completed.
- 24 Aug 2016 Planned End Date changed from 1 Jun 2016 to 1 Dec 2019.
- 04 May 2016 Planned End Date changed from 1 Mar 2016 to 1 Jun 2016.